Page last updated: 2024-11-05

lumazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Lumazine is a heterocyclic compound with a purine-like structure. It is a precursor to the biosynthesis of riboflavin (vitamin B2), a crucial coenzyme involved in various metabolic processes. Lumazine itself does not have known biological activity. It is synthesized from guanine through a series of enzymatic reactions. Lumazine's importance stems from its role as an intermediate in riboflavin production, making it a target of study for understanding vitamin B2 deficiency and potential therapeutic applications.'

lumazine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2,4-dihydroxypteridine : Any dihydroxypteridine in which the two hydroxy substituents are located at positions 2 and 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

lumazine : A 2,4-dihydroxypteridine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID10250
CHEMBL ID1234104
CHEBI ID16489
SCHEMBL ID321932
MeSH IDM0052020

Synonyms (67)

Synonym
OPREA1_489423
AKOS002337448
CHEMBL1234104
1h,3h-pteridine-2,4-dione
CHEBI:16489 ,
pteridine-2,4-diol
NSC41801 ,
2,8h)-pteridinedione
2,3h)-pteridinedione
nsc-41801
2,4-pteridinediol
nsc225113
nsc-225113
AB-323/25048461
pteridine-2,4(1h,3h)-dione
nsc 41801
einecs 207-652-7
lumazine (van)
lumazin
pteridine-2,4-diol monohydrate
nsc 225113
1h-pteridine-2,4-dione
2,4(1h,3h)-pteridinedione
487-21-8
pteridine-2,4-dione
lumazine
C03212
2,4-dihydroxypteridine
2,4(3h,8h)-pteridinedione
lumazine, 97%
L-8500
L-8520
LUZ ,
uyeuuxmdvnycam-uhfffaoysa-
inchi=1/c6h4n4o2/c11-5-3-4(8-2-1-7-3)9-6(12)10-5/h1-2h,(h2,8,9,10,11,12)
525-77-9
L0086
AKOS000121322
unii-260mf9u4wc
260mf9u4wc ,
BP-11303
FT-0628047
STL373614
lumazine [mi]
pyrazino[2,3-d]pyrimidine-2,4(1h,3h)-dione
pteridin-2,4-dione
pyrazino [2,3-d]pyrimidine- 2,4(1h,3h)-dione
SCHEMBL321932
DTXSID0060068
pteridinedione
AKOS024015255
pteridinedione, 2,4(1h,3h)-
mfcd00066250
1,2,3,4-tetrahydropteridine-2,4-dione
STL556695
lumazine; 2,4-dihydroxypteridine; 2,4-pteridinediol
HY-W037619
DS-13683
Q17189420
2,3,4,8-tetrahydropteridine-2,4-dione
EN300-21263
BBL037035
CS-0094050
A871885
2,4-(1h,3h)-pteridinedione
SY009609
Z104494912

Research Excerpts

Overview

Lumazine protein is a member of the riboflavin synthase superfamily. Lumazine protein acts as an electronic excited state transducer in bioluminescence of Photobacterium species.

ExcerptReferenceRelevance
"Lumazine protein is a member of the riboflavin synthase superfamily and the intense fluorescence is caused by non-covalently bound to 6,7-dimethyl 8-ribityllumazine. "( Generation of Fluorescent Bacteria with the Genes Coding for Lumazine Protein and Riboflavin Biosynthesis.
Choi, M; Lee, CY; Lee, E; Lim, S; Oh, E, 2021
)
2.31
"Lumazines are an important family of heterocyclic compounds present in biological systems as biosynthetic precursors and/or products of metabolic degradation. "( The photosensitizing activity of lumazine using 2'-deoxyguanosine 5'-monophosphate and HeLa cells as targets.
Cabrerizo, FM; Denofrio, MP; Hatz, S; Lorente, C; Ogilby, PR; Thomas, AH, 2009
)
2.08
"Lumazines are an important family of heterocyclic compounds present in biological systems as biosynthetic precursors and/or products of metabolic degradation."( Oxidation of 2'-deoxyadenosine 5'-monophosphate photoinduced by lumazine.
Denofrio, MP; Lorente, C; Thomas, AH, 2010
)
1.32
"Lumazine protein acts as an electronic excited state transducer in bioluminescence of Photobacterium species. "( (Trifluoromethyl)lumazine derivatives as 19F NMR probes for lumazine protein.
Bacher, A; Cushman, M; Lee, J; Patel, H; Patrick, DA; Scheuring, J, 1994
)
2.07
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
2,4-dihydroxypteridineAny dihydroxypteridine in which the two hydroxy substituents are located at positions 2 and 4.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
guanosine nucleotides degradation III1425

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1339468Inhibition of wild type PI3K p110alpha/p85alpha niSH2 (unknown origin) expressed in baculovirus infected sf9 cells assessed as reduction in PIP3 formation at 100 uM using PIP2 as substrate after 45 mins by fluorescence polarization assay relative to contr2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design.
AID1339469Inhibition of full length PI3Kalpha (unknown origin) assessed as reduction in PIP3 formation at 100 uM using PIP2 as substrate after 45 mins by fluorescence polarization assay relative to control2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (60)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (6.67)18.7374
1990's12 (20.00)18.2507
2000's20 (33.33)29.6817
2010's21 (35.00)24.3611
2020's3 (5.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 38.43

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index38.43 (24.57)
Research Supply Index4.11 (2.92)
Research Growth Index4.93 (4.65)
Search Engine Demand Index49.16 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (38.43)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (6.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other56 (93.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]